MABPRO, a.s. is a biotech company established in 2016, based in Bratislava, Slovakia.
Our biotechnology, research and development strategy come out from base technology and products related to unique endogenous marker of hypoxia – carbonic anhydrase IX (CA IX), which are protected by complex patent portfolio owned by Biomedical Research Center of the Slovak Academy of Sciences (BMC SAS). MABPRO, a.s. holds License to use all IP rights, technology and products related to CA IX in field of diagnostics and therapy.
Improve health and extend lives of cancer patients by developing new diagnostic and therapeutic modalities.
Our vision is based on the strong belief that specific diagnostics allows correct selection of targeted therapy and therapy success relies on the correct stratification of patients based on specific diagnostics.
Therefore, we have an ambition to build a strong and succesful business, in which the Therapeutic and Diagnostic division will be closely interconnected.
MABPRO team is a highly experienced group of top Slovak and world renowned researchers, clinicians and executives, with great skills in oncology, immunology, molecular biology and biotechnology.
We are also proud of our strong relationships and cooperation with top researchers from the BMC SAS, and top clinicians from the Jessenius Faculty of Medicine in Martin at the Comenius University in Bratislava.
Dúbravská cesta 2
841 04 Bratislava
ID. No.: 36 831 930
VAT Reg. No.: SK2022456678
Registered in Commercial register of Bratislava I District Court
Section: Sa, file no.: 6337/B